ClinicalTrials.gg
CompletedNCT01192139Updated May 21, 2015Results posted

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)

A Phase 1 interventional study of saxagliptin and metformin XR in Diabetes Mellitus, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-21.

Sponsored by AstraZeneca · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 10 studies testing saxagliptin in Diabetes Mellitus — none open to participants now, none under way, none of them phase 3. saxagliptin · Diabetes Mellitus.

Enrollment
8th of 10
30 · median 66
Started
2009
with 1 other
Phase 1
3 of 10
none open now
Registered
4th of 10
by date
Lead sponsor
7 of 10
AstraZeneca

Among the 10 studies testing saxagliptin in Diabetes Mellitus, this one is the 8th largest by enrollment, is one of 2 that started in 2009, is one of 3 in phase 1, and was the 4th registered.

Diabetes Mellitus

8,294 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

None of the 10 studies testing saxagliptin in Diabetes Mellitus is open now. The open studies under Diabetes Mellitus, anywhere →

About saxagliptin

saxagliptin: first FDA approval 2009 (ONGLYZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing saxagliptin in Diabetes Mellitus as a file.
02

Study summary

The purpose of this study is to demonstrate bioequivalence (BE) of a 5 mg saxagliptin/500 mg metformin extended release (XR) fixed-dose combination (FDC) tablet (manufactured in Mt Vernon, Indiana [IN]) to coadministered 5 mg saxagliptin and 500 mg metformin XR tablet (manufactured in Evansville, IN) in fed healthy subjects.

Read the detailed description

This study is designed to evaluate if the FDC tablet of 5 mg saxagliptin/500 mg metformin extended release (manufactured in Mt Vernon, Indiana) is bioequivalent to the coadministered 5 mg saxagliptin and 500 mg metformin XR tablet (manufactured in Evansville, Indiana)

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female subjects as determined by no deviation from normal in medical history, physical examination, (ECG), and clinical laboratory determinations
  • (BMI) of 18 to 32 kg/m2, inclusive
  • Ages 18 to 45, inclusive

Exclusion criteria

Exclusion Criteria:

  • Evidence of organ dysfunction or any deviation from normal in physical examination, vital signs, or clinical laboratory determinations beyond what is consistent with the target population
  • Major surgical procedure within 4 weeks prior to randomization
  • Positive serology test for (HIV), virus (HBV) or virus (HCV)
  • Clinically significant history or presence of any of the following conditions: heart, liver, or kidney disease, neurologic or psychiatric disease
  • History of gastrointestinal disease within the past 3 months
  • Any clinically significant medical condition that could potentially affect your participation in the study and/or personal well-being, as judged by the investigator
  • Donated blood or blood products to a blood bank, blood transfusion or participated in a clinical study (except a screening visit) requiring withdrawal of blood within 4 weeks prior to randomization
  • Unable to tolerate oral and/or intravenous (IV) medications
  • Unable to tolerate the puncturing of veins for drawing of blood
  • Known allergy or to any component of the study medication
  • History of any significant drug allergies (such as anaphylaxis or hepatotoxicity)
  • Used any prescription drugs or over the counter products to control acid (for example, Prevacid, Mylanta or Rolaids) within 4 weeks prior to randomization
  • Used any other drugs including over the counter medications and herbal preparations within 1 week prior to randomization
  • Taken any drug or placebo (inactive drug) within 4 weeks prior to randomization
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    5 mg saxagliptin + a single 500 mg metformin XR tablet

    Drug: saxagliptin · Drug: metformin XR

  • Experimental
    FDC tablet (5 mg saxagliptin + 500 mg metformin XR) (Fed)

    under fed state

    Drug: saxagliptin + metformin XR (FDC tablet)

  • Experimental
    FDC tablet (5 mg saxagliptin + 500 mg metformin XR) (Fasting)

    under fasted state

    Drug: saxagliptin + metformin XR (FDC tablet)

Interventions

  • Tablets, Oral, 5 mg, once daily, Single dose

    Also known as: Onglyza

  • Tablets, Oral, 500 mg. once daily, Single dose

    Also known as: Glucophage XR

  • Drugsaxagliptin + metformin XR (FDC tablet)

    Drug pages: Saxagliptin · Metformin

    Tablet, Oral, (saxagliptin 5 mg)(metformin XR 500 mg), once daily, Single dose

06

What researchers measure

Primary outcomes

  1. Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])

    Area under the plasma concentration versus time curve from time 0 extrapolated to infinity; calculated as AUC0-t \[calculated using the linear trapezoidal rule\] + Ct/Kel, where Ct was the last measurable concentration and Kel was the terminal rate constant

    Time frame: Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)

  2. Saxagliptin Observed Maximum Plasma Concentration (Cmax)

    Time frame: Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)

  3. Metformin AUC(0-inf)

    Area under the plasma concentration versus time curve from time 0 extrapolated to infinity; calculated as AUC0-t \[calculated using the linear trapezoidal rule\] + Ct/Kel, where Ct was the last measurable concentration and Kel was the terminal rate constant

    Time frame: Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)

  4. Metformin Cmax

    Time frame: Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)

Secondary outcomes

  1. Saxagliptin Terminal Half-life (T1/2)

    terminal half life; calculated as ln(2)/Kel

    Time frame: Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)

  2. Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])

    Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration (Ct), calculated using the linear trapezoidal rule.

    Time frame: Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)

  3. Time to Achieve the Observed Maximum Saxagliptin Plasma Concentration (Tmax)

    Time frame: Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)

  4. Saxagliptin Fraction of AUC(0-inf) Contributed by AUC(0-t) (AUC[0-t]/AUC[0-inf])

    Time frame: Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)

  5. Active Metabolite BMS-510849 AUC(0-inf)

    Area under the plasma concentration versus time curve from time 0 extrapolated to infinity; calculated as AUC0-t \[calculated using the linear trapezoidal rule\] + Ct/Kel, where Ct was the last measurable concentration and Kel was the terminal rate constant

    Time frame: Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)

  6. Active Metabolite BMS-510849 AUC(0-t)

    Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration (Ct), calculated using the linear trapezoidal rule.

    Time frame: Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)

  7. Active Metabolite BMS-510849 Cmax

    Time frame: Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)

  8. Active Metabolite BMS-510849 T1/2

    terminal half life; calculated as ln(2)/Kel

    Time frame: Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)

  9. Active Metabolite BMS-510849 Tmax

    Time frame: Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)

  10. Active Metabolite BMS-510849 AUC(0-t)/AUC(0-inf)

    Time frame: Period 1 (samples taken before dosing, and at 0.167,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8,10,12,18,24,36 and 48 hours after dosing)

  11. Metformin AUC(0-t)

    Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration (Ct), calculated using the linear trapezoidal rule.

    Time frame: Period 1 (samples taken before dosing, and at 0.167,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8,10,12,18,24,36 and 48 hours after dosing)

  12. Metformin T1/2

    terminal half life; calculated as ln(2)/Kel

    Time frame: Period 1 (before dosing, 0.167,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8,10,12,18,24,36 and 48 hours after dosing)

  13. Metformin Tmax

    Time frame: Periods 1, 2, and 3 (before dosing, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)

  14. Metformin Fraction of AUC(0-inf) Contributed by AUC(0-t)(AUC[0-t]/AUC[0-inf])

    Time frame: Period 1 (before dosing, 0.167,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8,10,12,18,24,36 and 48 hours after dosing)

  15. Safety: Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs)

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.

    Time frame: AEs: from initiation of study drug administration on Day 1/Period 1 through study discharge Day 3/Period 3. SAEs: from date of written consent until 30 days after discontinuation of dosing or participation in study if last scheduled visit occurred later.

  16. Safety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and Electrocardiogram (ECG) Abnormalities

    Abnormalities considered by the investigator to be clinically significant and/or reported as an AE.

    Time frame: From Day 1 of Period 1 through Day 3 of Period 3 (study discharge)

07

Results

Posted May 17, 2011

Participant flow

Period 1
Participant flow — Period 1
MilestoneTreatment Sequence ABCTreatment Sequence ACBTreatment Sequence BACTreatment Sequence BCATreatment Sequence CABTreatment Sequence CBA
Started555555
Completed555555
Not completed000000
Period 2
Participant flow — Period 2
MilestoneTreatment Sequence ABCTreatment Sequence ACBTreatment Sequence BACTreatment Sequence BCATreatment Sequence CABTreatment Sequence CBA
Started555555
Completed555555
Not completed000000
Period 3
Participant flow — Period 3
MilestoneTreatment Sequence ABCTreatment Sequence ACBTreatment Sequence BACTreatment Sequence BCATreatment Sequence CABTreatment Sequence CBA
Started555555
Completed555555
Not completed000000

Outcome measures

PrimarySaxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])

Area under the plasma concentration versus time curve from time 0 extrapolated to infinity; calculated as AUC0-t \[calculated using the linear trapezoidal rule\] + Ct/Kel, where Ct was the last measurable concentration and Kel was the terminal rate constant

Time frame:
Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)
Reported as:
Mean · ng*hr/mL
Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])
ng*hr/mLTreatment A - Saxagliptin + Metformin XR, FedTreatment B - FDC Tablet (Saxagliptin + Metformin XR), FedTreatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting
Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])107.28 ± 25.13111.72 ± 26.55103.35 ± 23.15
Statistical analysis
  • Treatment A - Saxagliptin + Metformin XR, Fed vs Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed · Ratio of geometric least squares means: 1.039 · 90% CI 1.011 to 1.068Ratio=Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries.
  • Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed vs Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting · Ratio of least squares means: 1.078 · 90% CI 1.049 to 1.108Ratio=Treatment B/Treatment C. Geometric least squares means values are presented in other statistical analysis entries.
  • Treatment A - Saxagliptin + Metformin XR, Fed · Geometric least squares mean (ng*hr/ml): 104.65
  • Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed · Geometric least squares mean (ng*hr/ml): 108.74
  • Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting · Geometric least squares mean (ng*hr/ml): 100.84
SecondarySaxagliptin Terminal Half-life (T1/2)

terminal half life; calculated as ln(2)/Kel

Time frame:
Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)
Reported as:
Mean · hours
Saxagliptin Terminal Half-life (T1/2)
hoursTreatment A - Saxagliptin + Metformin XR, FedTreatment B - FDC Tablet (Saxagliptin + Metformin XR), FedTreatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting
Saxagliptin Terminal Half-life (T1/2)8.46 ± 2.858.56 ± 3.049.21 ± 3.91
SecondarySaxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])

Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration (Ct), calculated using the linear trapezoidal rule.

Time frame:
Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)
Reported as:
Mean · ng*hr/mL
Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])
ng*hr/mLTreatment A - Saxagliptin + Metformin XR, FedTreatment B - FDC Tablet (Saxagliptin + Metformin XR), FedTreatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting
Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])105.47 ± 24.98109.88 ± 26.36101.52 ± 23.01
Statistical analysis
  • Treatment A - Saxagliptin + Metformin XR, Fed vs Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed · Ratio of geometric least squares mean: 1.039 · 90% CI 1.011 to 1.068Ratio = Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries.
  • Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed vs Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting · Ratio of geometric least squares means: 1.080 · 90% CI 1.051 to 1.110Ratio=Treatment B/Treatment C. Geometric least squares means values are presented in other statistical analysis entries.
  • Treatment A - Saxagliptin + Metformin XR, Fed · Geometric least squares mean (ng*hr/ml): 102.84
  • Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed · Geometric least squares mean (ng*hr/ml): 106.89
  • Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting · Geometric least squares mean (ng*hr/ml): 98.99
PrimarySaxagliptin Observed Maximum Plasma Concentration (Cmax)
Time frame:
Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)
Reported as:
Mean · ng/mL
Saxagliptin Observed Maximum Plasma Concentration (Cmax)
ng/mLTreatment A - Saxagliptin + Metformin XR, FedTreatment B - FDC Tablet (Saxagliptin + Metformin XR), FedTreatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting
Saxagliptin Observed Maximum Plasma Concentration (Cmax)26.84 ± 8.2627.25 ± 7.9528.85 ± 8.62
Statistical analysis
  • Treatment A - Saxagliptin + Metformin XR, Fed vs Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed · Ratio of geometric least squares means: 1.021 · 90% CI 0.940 to 1.109Ratio=Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries.
  • Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed vs Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting · Ratio of geometric least squares means: 0.949 · 90% CI 0.873 to 1.031Ratio = Treatment B/Treatment C. Geometric least squares means values are presented in other statistical analysis entries.
  • Treatment A - Saxagliptin + Metformin XR, Fed · Geometric least squares mean (ng*hr/ml): 25.68
  • Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed · Geometric least squares mean (ng*hr/ml): 26.21
  • Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting · Geometric least squares mean (ng*hr/ml): 27.63
SecondaryTime to Achieve the Observed Maximum Saxagliptin Plasma Concentration (Tmax)
Time frame:
Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)
Reported as:
Mean · hours
Time to Achieve the Observed Maximum Saxagliptin Plasma Concentration (Tmax)
hoursTreatment A - Saxagliptin + Metformin XR, FedTreatment B - FDC Tablet (Saxagliptin + Metformin XR), FedTreatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting
Time to Achieve the Observed Maximum Saxagliptin Plasma Concentration (Tmax)1.65 ± 0.651.48 ± 0.750.65 ± 0.50
SecondarySaxagliptin Fraction of AUC(0-inf) Contributed by AUC(0-t) (AUC[0-t]/AUC[0-inf])
Time frame:
Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)
Reported as:
Mean · ratio
Saxagliptin Fraction of AUC(0-inf) Contributed by AUC(0-t) (AUC[0-t]/AUC[0-inf])
ratioTreatment A - Saxagliptin + Metformin XR, FedTreatment B - FDC Tablet (Saxagliptin + Metformin XR), FedTreatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting
Saxagliptin Fraction of AUC(0-inf) Contributed by AUC(0-t) (AUC[0-t]/AUC[0-inf])0.983 ± 0.0060.983 ± 0.0060.982 ± 0.008
SecondaryActive Metabolite BMS-510849 AUC(0-inf)

Area under the plasma concentration versus time curve from time 0 extrapolated to infinity; calculated as AUC0-t \[calculated using the linear trapezoidal rule\] + Ct/Kel, where Ct was the last measurable concentration and Kel was the terminal rate constant

Time frame:
Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)
Reported as:
Mean · ng*hr/mL
Active Metabolite BMS-510849 AUC(0-inf)
ng*hr/mLTreatment A - Saxagliptin + Metformin XR, FedTreatment B - FDC Tablet (Saxagliptin + Metformin XR), FedTreatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting
Active Metabolite BMS-510849 AUC(0-inf)291.72 ± 79.21295.94 ± 75.40289.06 ± 66.89
SecondaryActive Metabolite BMS-510849 AUC(0-t)

Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration (Ct), calculated using the linear trapezoidal rule.

Time frame:
Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)
Reported as:
Mean · ng*hr/mL
Active Metabolite BMS-510849 AUC(0-t)
ng*hr/mLTreatment A - Saxagliptin + Metformin XR, FedTreatment B - FDC Tablet (Saxagliptin + Metformin XR), FedTreatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting
Active Metabolite BMS-510849 AUC(0-t)284.46 ± 78.25289.03 ± 74.80281.79 ± 65.91
SecondaryActive Metabolite BMS-510849 Cmax
Time frame:
Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)
Reported as:
Mean · ng/mL
Active Metabolite BMS-510849 Cmax
ng/mLTreatment A - Saxagliptin + Metformin XR, FedTreatment B - FDC Tablet (Saxagliptin + Metformin XR), FedTreatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting
Active Metabolite BMS-510849 Cmax49.71 ± 16.9449.28 ± 14.5949.09 ± 15.46
SecondaryActive Metabolite BMS-510849 T1/2

terminal half life; calculated as ln(2)/Kel

Time frame:
Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)
Reported as:
Mean · hours
Active Metabolite BMS-510849 T1/2
hoursTreatment A - Saxagliptin + Metformin XR, FedTreatment B - FDC Tablet (Saxagliptin + Metformin XR), FedTreatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting
Active Metabolite BMS-510849 T1/213.88 ± 1.5313.65 ± 1.7214.04 ± 1.33
SecondaryActive Metabolite BMS-510849 Tmax
Time frame:
Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)
Reported as:
Mean · hours
Active Metabolite BMS-510849 Tmax
hoursTreatment A - Saxagliptin + Metformin XR, FedTreatment B - FDC Tablet (Saxagliptin + Metformin XR), FedTreatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting
Active Metabolite BMS-510849 Tmax2.38 ± 0.762.42 ± 0.881.46 ± 0.70
SecondaryActive Metabolite BMS-510849 AUC(0-t)/AUC(0-inf)
Time frame:
Period 1 (samples taken before dosing, and at 0.167,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8,10,12,18,24,36 and 48 hours after dosing)
Reported as:
Mean · ratio
Active Metabolite BMS-510849 AUC(0-t)/AUC(0-inf)
ratioTreatment A - Saxagliptin + Metformin XR, FedTreatment B - FDC Tablet (Saxagliptin + Metformin XR), FedTreatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting
Active Metabolite BMS-510849 AUC(0-t)/AUC(0-inf)0.974 ± 0.0080.975 ± 0.0080.974 ± 0.006
PrimaryMetformin AUC(0-inf)

Area under the plasma concentration versus time curve from time 0 extrapolated to infinity; calculated as AUC0-t \[calculated using the linear trapezoidal rule\] + Ct/Kel, where Ct was the last measurable concentration and Kel was the terminal rate constant

Time frame:
Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)
Reported as:
Mean · ng*hr/mL
Metformin AUC(0-inf)
ng*hr/mLTreatment A - Saxagliptin + Metformin XR, FedTreatment B - FDC Tablet (Saxagliptin + Metformin XR), FedTreatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting
Metformin AUC(0-inf)5865.92 ± 2357.155516.97 ± 2423.085073.70 ± 1406.45
Statistical analysis
  • Treatment A - Saxagliptin + Metformin XR, Fed vs Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed · Ratio of least squares geometric means: 0.915 · 90% CI 0.836 to 1.002Ratio = Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries.
  • Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed vs Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting · Ratio of geometric ls mean and 90% ci: 1.010 · 90% CI 0.918 to 1.111Ratio = Treatment B/Treatment C. Geometric least squares means values are presented in other statistical analysis entries.
  • Treatment A - Saxagliptin + Metformin XR, Fed · Geometric least squares mean (ng*hr/ml): 5542.2
  • Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed · Geometric least squares mean (ng*hr/ml): 5072.9
  • Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting · Geometric least squares mean (ng*hr/ml): 5023.3
SecondaryMetformin AUC(0-t)

Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration (Ct), calculated using the linear trapezoidal rule.

Time frame:
Period 1 (samples taken before dosing, and at 0.167,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8,10,12,18,24,36 and 48 hours after dosing)
Reported as:
Mean · ng*hr/mL
Metformin AUC(0-t)
ng*hr/mLTreatment A - Saxagliptin + Metformin XR, FedTreatment B - FDC Tablet (Saxagliptin + Metformin XR), FedTreatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting
Metformin AUC(0-t)5617.39 ± 2181.995200.46 ± 2203.344896.95 ± 1340.41
Statistical analysis
  • Treatment A - Saxagliptin + Metformin XR, Fed vs Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed · Ratio of geometric least squares mean: 0.920 · 90% CI 0.854 to 0.992Ratio=Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries.
  • Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed vs Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting · Ratio of geometric least squares means: 1.025 · 95% CI 0.951 to 1.105Ratio=Treatment B/Treatment C. Geometric least squares means values are presented in other statistical analysis entries.
  • Treatment A - Saxagliptin + Metformin XR, Fed · Geometric least squares mean (ng*hr/ml): 5287.1
  • Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed · Geometric least squares mean (ng*hr/ml): 4866.2
  • Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting · Geometric least squares mean (ng*hr/ml): 4746.8
PrimaryMetformin Cmax
Time frame:
Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)
Reported as:
Mean · ng/mL
Metformin Cmax
ng/mLTreatment A - Saxagliptin + Metformin XR, FedTreatment B - FDC Tablet (Saxagliptin + Metformin XR), FedTreatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting
Metformin Cmax629.73 ± 160.14586.87 ± 150.63657.23 ± 187.67
Statistical analysis
  • Treatment A - Saxagliptin + Metformin XR, Fed vs Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed · Ratio of geometric least squares means: 0.933 · 95% CI 0.865 to 1.007Ratio = Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries.
  • Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed vs Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting · Ratio of geometric least squares means: 0.898 · 90% CI 0.832 to 0.969Ration = Treatment B/Treatment C. Geometric least squares means values are presented in other statistical analysis entries.
  • Treatment A - Saxagliptin + Metformin XR, Fed · Geometric least squares mean (ng*hr/ml): 608.41
  • Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed · Geometric least squares mean (ng*hr/ml): 567.85
  • Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting · Geometric least squares mean (ng*hr/ml): 632.39
SecondaryMetformin T1/2

terminal half life; calculated as ln(2)/Kel

Time frame:
Period 1 (before dosing, 0.167,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8,10,12,18,24,36 and 48 hours after dosing)
Reported as:
Mean · hours
Metformin T1/2
hoursTreatment A - Saxagliptin + Metformin XR, FedTreatment B - FDC Tablet (Saxagliptin + Metformin XR), FedTreatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting
Metformin T1/210.7 ± 5.9012.6 ± 7.0514.9 ± 7.40
SecondaryMetformin Tmax
Time frame:
Periods 1, 2, and 3 (before dosing, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)
Reported as:
Mean · hours
Metformin Tmax
hoursTreatment A - Saxagliptin + Metformin XR, FedTreatment B - FDC Tablet (Saxagliptin + Metformin XR), FedTreatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting
Metformin Tmax4.78 ± 1.044.90 ± 1.134.11 ± 0.88
SecondaryMetformin Fraction of AUC(0-inf) Contributed by AUC(0-t)(AUC[0-t]/AUC[0-inf])
Time frame:
Period 1 (before dosing, 0.167,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8,10,12,18,24,36 and 48 hours after dosing)
Reported as:
Mean · ratio
Metformin Fraction of AUC(0-inf) Contributed by AUC(0-t)(AUC[0-t]/AUC[0-inf])
ratioTreatment A - Saxagliptin + Metformin XR, FedTreatment B - FDC Tablet (Saxagliptin + Metformin XR), FedTreatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting
Metformin Fraction of AUC(0-inf) Contributed by AUC(0-t)(AUC[0-t]/AUC[0-inf])0.979 ± 0.0200.970 ± 0.0260.965 ± 0.031
SecondarySafety: Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs)

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.

Time frame:
AEs: from initiation of study drug administration on Day 1/Period 1 through study discharge Day 3/Period 3. SAEs: from date of written consent until 30 days after discontinuation of dosing or participation in study if last scheduled visit occurred later.
Reported as:
Number · Participants
Safety: Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs)
ParticipantsTreatment A - Saxagliptin + Metformin XR, FedTreatment B - FDC Tablet (Saxagliptin + Metformin XR), FedTreatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting
Number of Participants With At Least 1 AE324
Discontinuation Due to an AE000
Deaths000
SAEs000
SecondarySafety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and Electrocardiogram (ECG) Abnormalities

Abnormalities considered by the investigator to be clinically significant and/or reported as an AE.

Time frame:
From Day 1 of Period 1 through Day 3 of Period 3 (study discharge)
Reported as:
Number · Participants
Safety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and Electrocardiogram (ECG) Abnormalities
ParticipantsTreatment A - Saxagliptin + Metformin XR, FedTreatment B - FDC Tablet (Saxagliptin + Metformin XR), FedTreatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting
Clinical Laboratory Abnormalities000
Vital Sign Abnormalities000
Physical Examination Abnormalities000
12-Lead ECG Abnormalities000

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A—0/30 (0%)3/30 (10%)
Treatment C—0/30 (0%)4/30 (13.3%)
Treatment B—0/30 (0%)2/30 (6.7%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventTreatment ATreatment CTreatment B
HEADACHENervous system disorders0/301/301/30
PRESYNCOPENervous system disorders0/301/300/30
NAUSEAGastrointestinal disorders0/301/300/30
DIARRHOEAGastrointestinal disorders0/301/301/30
DRY MOUTHGastrointestinal disorders0/301/300/30
FLATULENCEGastrointestinal disorders0/300/301/30
CHAPPED LIPSGastrointestinal disorders0/301/300/30
CONSTIPATIONGastrointestinal disorders0/300/301/30
LIP SWELLINGGastrointestinal disorders1/300/300/30
ABDOMINAL DISTENSIONGastrointestinal disorders0/300/301/30

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Enrolled and Treated Participants
Mean29.1 ± 8.0
Sex: Female, Male
Sex: Female, Male(Participants)All Enrolled and Treated Participants
Female14
Male16
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)All Enrolled and Treated Participants
White17
Black or African American12
Asian1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)All Enrolled and Treated Participants
Hispanic or Latino9
Not Hispanic or Latino21
Height
Height(cm)All Enrolled and Treated Participants
Mean170.0 ± 9.22
Weight
Weight(kg)All Enrolled and Treated Participants
Mean78.31 ± 13.74
Body Mass Index
Body Mass Index(kg/m^2)All Enrolled and Treated Participants
Mean26.97 ± 3.07
08

Study locations

1 site
  • Ppd Development, Lp
    Austin, Texas 78744, United States
09

References and documents

Publications

  • Boulton DW, Smith CH, Li L, Huang J, Tang A, LaCreta FP. Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects. Clin Drug Investig. 2011;31(9):619-30. doi: 10.2165/11590290-000000000-00000. PubMed 21819160 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2010
First posted
Aug 31, 2010
Start
Nov 2009
Primary completionActual
Dec 2009
CompletionActual
Dec 2009
Results first posted
May 17, 2011
Last update
May 21, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01192139
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 31, 2010
Start date
Nov 2009
Primary completion
Dec 2009
Completion
Dec 2009
Results posted
May 17, 2011
Last update
May 21, 2015

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Saxagliptin · Metformin

Start the discussion